

Attorney Docket No. Le A 36 252

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gielen-Haertwig, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/009108

Title: Dihydropyridinone Derivatives

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Tilman Breitenstein
Limited Recognition under 37 CFR § 11.9(b)
Agent for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-2226
Facsimile: (203) 812-6459

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.